Quick answer
What is the mechanism of action of BPC-157? No single receptor has been established in the papers reviewed. The literature proposes pathways: FAK-paxillin activation and migration in tendon fibroblasts, VEGFR2-Akt-eNOS signaling in endothelial cells, increased growth hormone receptor expression, and interaction with the nitric oxide and neurotransmitter systems. Most evidence is correlative cell and rodent work from few laboratories; necessity tests are scarce. For laboratory research use only.
Ask what BPC-157 does at the molecular level and the honest answer is a list of pathways, not a receptor. Over two decades, published experiments have connected the peptide to focal adhesion signaling, to a vascular endothelial growth factor receptor, to growth hormone receptor expression, to the nitric oxide system and to several neurotransmitter systems, yet no single high-affinity binding site has been established in the papers reviewed here. This article lays out each proposed mechanism, the assay behind it, how strong the evidence is and what a laboratory can do to test it. It is written for people who work with the BPC-157 research peptide; all material is for laboratory research use only, and nothing here describes effects in people.
The starting point: a stable peptide with a broad phenotype
BPC-157 is a synthetic pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, corresponding to a segment of a protein first isolated from gastric juice. The observation that gave rise to the mechanistic literature is phenotypic: in animal models of tendon, gut, vascular and nervous tissue injury, authors report improved healing or protection (see the overview). A phenotype that broad usually means either that the agent acts on a very general process, such as blood supply or cell survival, or that several different effects were measured under one name. The mechanistic papers try to decide which. A 2019 review by Gwyer and colleagues says directly that the precise healing mechanisms still need to be understood, and the 2017 angiogenesis paper opens with the statement that the underlying mechanism of BPC-157’s contribution to angiogenesis was not yet clear.
Proposed mechanisms and the assays behind them
The table summarizes the main proposals. The "evidence type" column matters as much as the pathway: a phosphorylation change in cultured cells is a weaker basis for a mechanism than a pathway shown to be necessary for the effect in an intact animal.
| Proposed mechanism | System and readout reported | Evidence type | Source |
|---|---|---|---|
| FAK-paxillin activation promoting cell migration | Rat tendon fibroblasts; phospho-FAK and phospho-paxillin by Western blot, transwell migration, F-actin staining | Correlative in cell culture | Chang et al., 2011 |
| Increased growth hormone receptor expression | Rat tendon fibroblasts; cDNA microarray confirmed by RT-PCR and Western blot; JAK2 activation after growth hormone | Gene and protein expression in cell culture | Chang et al., 2014 |
| VEGFR2-Akt-eNOS signaling and VEGFR2 internalization | Chick chorioallantoic membrane, endothelial tube formation, rat hind-limb ischemia, human endothelial cells; dynasore as an endocytosis inhibitor | Cell and animal, with a pharmacologic inhibitor | Hsieh et al., 2017 |
| Nitric oxide system interaction | L-arginine and L-NAME experiments in rat models | Pharmacological interaction in animals | Sikiric et al., 2011; Seiwerth et al., 2014 |
| Egr-1, NAB2 and JAK-2 pathways; serotonergic and dopaminergic modulation | Gene expression and neurotransmitter assays in rats | Indirect, mostly summarized in reviews | Sikiric et al., 2016; Vukojevic et al., 2022 |
| Cell survival under oxidative stress | Hydrogen peroxide challenge of tendon fibroblasts | Cell culture | Chang et al., 2011 |
Reading across the rows, three themes recur: cell migration and adhesion, vascular function and growth-factor receptor signaling. They are not mutually exclusive, and a simple unifying model would link them through endothelial function and nitric oxide, which is how the founding group’s reviews often frame the results.
Focal adhesion signaling and migration
Focal adhesion kinase and paxillin are scaffold and signaling proteins at sites where a cell attaches to its matrix, and their phosphorylation tracks adhesion turnover and cell movement. In the 2011 tendon fibroblast study, the peptide increased phosphorylation of both proteins in a dose-dependent manner while the total amounts of the proteins were unchanged, increased F-actin formation and increased migration and spreading in transwell and culture-dish assays. Proliferation by MTT assay was not directly affected. The authors concluded that the effects were likely mediated by the FAK-paxillin pathway.
What would strengthen this mechanism is necessity evidence: does a FAK inhibitor or a knockdown of FAK or paxillin abolish the migration effect? The abstract does not report such an experiment. A laboratory can design it with standard tools, using a FAK inhibitor arm alongside the peptide and vehicle arms and keeping the stock preparation identical across arms.
Vascular signaling: VEGFR2 and nitric oxide
The 2017 study by Hsieh and colleagues is the most detailed mechanistic paper in this set. It reports that the peptide increased vessel density in the chick chorioallantoic membrane assay and in endothelial tube formation, accelerated blood flow recovery in ischemic rat hind-limb muscle as measured by laser Doppler, and increased the number of vessels and vascular VEGFR2 expression in histology. In human vascular endothelial cells, VEGFR2 mRNA and protein increased while VEGF-A did not, the peptide promoted VEGFR2 internalization, and it time-dependently activated a VEGFR2-Akt-eNOS signaling pathway. Dynasore, which inhibits endocytosis, blocked internalization, pathway activation and the increase in tube formation, which gives the paper a necessity test that most of the cell-level work lacks.
The nitric oxide relationship is older and broader. The review of vascular effects (Seiwerth et al., 2014) describes BPC-157 as acting through several vasoactive pathways and systems, including NO, VEGF and FAK, and the 2011 gastrointestinal review describes experiments in which the NO precursor L-arginine and the NO synthase inhibitor L-NAME were used to probe the interaction. The findings described there depend on the model and are discussed by the authors as an interplay with the NO system rather than a single direction of effect.
Growth hormone receptor expression
The 2014 study asked an unbiased question: which genes change when tendon fibroblasts are exposed to BPC-157? Growth hormone receptor was among the most abundantly up-regulated, and its mRNA and protein increased in a dose- and time-dependent manner. When growth hormone was then added, proliferation (by MTT and PCNA expression) rose and JAK2 was activated in a time-dependent manner. The authors interpret the result as potentiation of the proliferative response to growth hormone, which would be an indirect mechanism: the peptide changes how responsive cells are to another signal, rather than acting as a signal itself. This fits the 2011 finding that the peptide had no direct effect on proliferation.
Central nervous system mechanisms
The nervous-system literature adds serotonergic and dopaminergic modulation and the nitric oxide system to the mechanistic list. The 2016 brain-gut review reports that peripheral administration changed serotonin release in nigrostriatal regions and modulated dopaminergic and serotonergic function in behavioral models, and the 2022 review lists effects in rat models of stroke, catalepsy induced by L-NAME or haloperidol, psychosis-like behavior, and spinal cord compression. These results come from in-vivo behavioral and histological experiments and are largely reported by the same group. They are mechanistically interesting because they involve systems unrelated to tendon or endothelium, which raises the question of whether the peptide has a general action on, for example, nitric oxide signaling, or acts on several systems independently.
Open questions and how to test them in the laboratory
Four questions are unresolved in the papers reviewed here. Is there a receptor or binding partner, and if so, what is its affinity? Which pathway is necessary rather than merely correlated? Are the effects reproducible in independent laboratories and in human cell systems? And what is the concentration-response relationship in a defined cell system, given that animal amounts per kilogram do not transfer to culture? The table lists experiments that would address them.
| Question | Experiment | Notes |
|---|---|---|
| Is there a binding partner? | Affinity pull-down with a tagged peptide; surface plasmon resonance; competition binding | Requires a modified or labeled peptide and appropriate negative controls |
| Is FAK-paxillin signaling necessary? | FAK inhibitor or knockdown arm in migration assay | Compare with vehicle and scrambled peptide |
| Is VEGFR2 signaling necessary? | VEGFR2 inhibitor, receptor knockdown, endocytosis inhibitor | Dynasore was used in the 2017 study |
| Does the effect replicate? | Independent laboratory, defined lot, blinded scoring | Document lot, purity method and thaw history |
| What is the concentration-response? | Log-spaced series with a vehicle control | State units and verify the stock |
Each experiment depends on a well-characterized stock. Use a documented lot (see BPC-157 purity testing, the COA library and how to read a COA), prepare it by a defined method (how to reconstitute a lyophilized peptide), compute concentrations with the reconstitution calculator, and consider the comparison with another repair-associated peptide in BPC-157 vs TB-500, whose proposed mechanism centers on actin rather than on the pathways above.
Frequently asked questions
Does BPC-157 have a known receptor?
None of the papers reviewed here establishes a single high-affinity receptor. The literature describes signaling pathways such as FAK-paxillin and VEGFR2-Akt-eNOS rather than a defined binding site.
What is the FAK-paxillin finding?
In rat tendon fibroblasts, a 2011 study reported dose-dependent increases in phosphorylation of FAK and paxillin with increased migration and spreading, and concluded that the effect was likely mediated through that pathway.
What did the VEGFR2 study show?
A 2017 study reported increased vessel density in chorioallantoic membrane and tube formation assays, faster blood flow recovery in ischemic rat muscle, increased VEGFR2 expression and internalization, and activation of VEGFR2-Akt-eNOS signaling, blocked by dynasore.
Does BPC-157 increase VEGF-A expression?
In the 2017 human endothelial cell experiments, VEGFR2 expression increased but VEGF-A did not.
How does growth hormone receptor fit in?
A 2014 study found growth hormone receptor among the most up-regulated genes in tendon fibroblasts exposed to the peptide, and growth hormone then increased proliferation and JAK2 activation, suggesting potentiation of an existing signal.
Why does the nitric oxide system keep appearing?
Several reviews describe experiments with L-arginine and L-NAME in rats showing that the peptide interacts with the NO system. The direction of the interaction depends on the model.
Is the mechanism settled?
No. A 2019 review says the precise healing mechanisms still need to be understood, and the 2017 angiogenesis paper states that the mechanism was not yet clear before its experiments.
Which experiment would show a pathway is necessary?
An inhibitor or knockdown arm that abolishes the effect, run alongside vehicle and scrambled-peptide controls. The 2017 study used dynasore, an endocytosis inhibitor, as such a test.
Why does the lot matter for mechanism work?
Impurities, degradation or an uncertain concentration can create or hide effects. A documented lot, a defined preparation and a verified stock make results reproducible.
Is this evidence applicable to people?
The cited work is preclinical and the compound is not an FDA-approved drug. All material is sold for laboratory research use only.
Related reading: BPC-157 and TB-500 Storage and Stability Compared, BPC-157 and TB-500 Testing: What a Certificate Must Show, Why BPC-157 and TB-500 Are Paired in Research.
References
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
- Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066
- Hsieh MJ, Lee CH, Chueh HY, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y
- Seiwerth S, Brcic L, Vuletic LB, Kolenc D, Aralica G, Misic M, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-1125. doi:10.2174/13816128113199990421
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632. doi:10.2174/138161211796196954
- Sikiric P, Rucman R, Turkovic B, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. doi:10.2174/1570159x13666160502153022
- Vukojevic J, Milavic M, Perovic D, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482. doi:10.4103/1673-5374.320969
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
